Oncobiologics (OTLK) Competitors $1.09 +0.03 (+2.83%) Closing price 04:00 PM EasternExtended Trading$1.10 +0.00 (+0.46%) As of 06:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock OTLK vs. SXTC, FTLF, DERM, SCLX, GNFT, FBRX, MIST, PLX, AVTX, and TARAShould you be buying Oncobiologics stock or one of its competitors? The main competitors of Oncobiologics include China SXT Pharmaceuticals (SXTC), FitLife Brands (FTLF), Journey Medical (DERM), Scilex (SCLX), GENFIT (GNFT), Forte Biosciences (FBRX), Milestone Pharmaceuticals (MIST), Protalix BioTherapeutics (PLX), Avalo Therapeutics (AVTX), and Protara Therapeutics (TARA). These companies are all part of the "pharmaceutical products" industry. Oncobiologics vs. Its Competitors China SXT Pharmaceuticals FitLife Brands Journey Medical Scilex GENFIT Forte Biosciences Milestone Pharmaceuticals Protalix BioTherapeutics Avalo Therapeutics Protara Therapeutics Oncobiologics (NASDAQ:OTLK) and China SXT Pharmaceuticals (NASDAQ:SXTC) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, earnings, media sentiment, profitability, dividends, risk and institutional ownership. Do analysts rate OTLK or SXTC? Oncobiologics currently has a consensus target price of $7.00, suggesting a potential upside of 542.20%. Given Oncobiologics' stronger consensus rating and higher probable upside, equities research analysts clearly believe Oncobiologics is more favorable than China SXT Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Oncobiologics 1 Sell rating(s) 4 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.14China SXT Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Which has more risk & volatility, OTLK or SXTC? Oncobiologics has a beta of 0.56, suggesting that its share price is 44% less volatile than the S&P 500. Comparatively, China SXT Pharmaceuticals has a beta of 1.36, suggesting that its share price is 36% more volatile than the S&P 500. Which has preferable valuation and earnings, OTLK or SXTC? China SXT Pharmaceuticals has higher revenue and earnings than Oncobiologics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOncobiologicsN/AN/A-$75.37M-$0.57-1.91China SXT Pharmaceuticals$1.74M108.69-$3.30MN/AN/A Is OTLK or SXTC more profitable? Company Net Margins Return on Equity Return on Assets OncobiologicsN/A N/A -332.30% China SXT Pharmaceuticals N/A N/A N/A Does the media refer more to OTLK or SXTC? In the previous week, Oncobiologics had 5 more articles in the media than China SXT Pharmaceuticals. MarketBeat recorded 7 mentions for Oncobiologics and 2 mentions for China SXT Pharmaceuticals. Oncobiologics' average media sentiment score of 0.59 beat China SXT Pharmaceuticals' score of 0.48 indicating that Oncobiologics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Oncobiologics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive China SXT Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do insiders & institutionals hold more shares of OTLK or SXTC? 11.2% of Oncobiologics shares are held by institutional investors. Comparatively, 5.0% of China SXT Pharmaceuticals shares are held by institutional investors. 4.8% of Oncobiologics shares are held by insiders. Comparatively, 4.0% of China SXT Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. SummaryOncobiologics beats China SXT Pharmaceuticals on 7 of the 11 factors compared between the two stocks. Get Oncobiologics News Delivered to You Automatically Sign up to receive the latest news and ratings for OTLK and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding OTLK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart OTLK vs. The Competition Export to ExcelMetricOncobiologicsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$48.42M$3.34B$6.10B$10.61BDividend YieldN/A2.28%5.64%4.70%P/E Ratio-1.9122.1685.6627.12Price / SalesN/A264.73526.70205.97Price / CashN/A46.3226.3031.12Price / Book-0.359.9412.906.66Net Income-$75.37M-$52.35M$3.30B$275.95M7 Day Performance2.83%5.93%4.79%3.31%1 Month Performance16.58%11.57%8.10%10.75%1 Year Performance-79.16%24.90%75.73%33.53% Oncobiologics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)OTLKOncobiologics2.926 of 5 stars$1.09+2.8%$7.00+542.2%-79.7%$48.42MN/A-1.9120SXTCChina SXT Pharmaceuticals0.5403 of 5 stars$1.62-0.6%N/A-71.2%$187.97M$1.74M0.0090Gap DownFTLFFitLife Brands3.8553 of 5 stars$19.91+0.2%$23.00+15.5%+23.1%$186.96M$64.47M23.7020DERMJourney Medical1.4999 of 5 stars$7.10+0.6%$12.17+71.4%+12.3%$186.80M$56.13M-18.6890SCLXScilex2.4093 of 5 stars$26.62-8.9%$455.00+1,609.2%-54.0%$185.28M$56.59M-0.9280GNFTGENFIT1.474 of 5 stars$3.65+2.8%$7.00+91.8%-25.7%$182.50M$76.77M0.00120Gap UpFBRXForte Biosciences3.121 of 5 stars$14.48+4.6%$68.00+369.6%+208.6%$179.99MN/A-0.895Positive NewsMISTMilestone Pharmaceuticals1.8266 of 5 stars$2.03+1.5%$4.50+121.7%+40.7%$172.53M$1M-2.4230News CoveragePositive NewsPLXProtalix BioTherapeutics2.7547 of 5 stars$2.16+4.9%$15.00+594.4%+125.0%$172.22M$61.95M-16.62200AVTXAvalo Therapeutics3.2886 of 5 stars$13.02+20.6%$31.67+143.2%+37.2%$171.21M$440K0.0040High Trading VolumeTARAProtara Therapeutics1.7641 of 5 stars$4.41+3.8%$19.60+344.4%+177.1%$170.14MN/A-2.7230Positive News Related Companies and Tools Related Companies China SXT Pharmaceuticals Competitors FitLife Brands Competitors Journey Medical Competitors Scilex Competitors GENFIT Competitors Forte Biosciences Competitors Milestone Pharmaceuticals Competitors Protalix BioTherapeutics Competitors Avalo Therapeutics Competitors Protara Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:OTLK) was last updated on 10/6/2025 by MarketBeat.com Staff From Our PartnersArizona-made nanochips the new millionaire maker?George Gilder handed President Reagan the first microchip that helped create $6.5 trillion in wealth over the ...Banyan Hill Publishing | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredThe $20 stock that could make silicon chips obsolete$2 TRILLION Quantum Gold Rush While everyone fights over expensive AI stocks... McKinsey just revealed the ...The Oxford Club | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oncobiologics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Oncobiologics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
